Chemo Pharma Laboratories Ltd Stock Price Today (NSE: CHEMOPH)
Fundamental Score
Chemo Pharma Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Chemo Pharma Laboratories Ltd share price today is ₹109.00, up +0.00% on NSE/BSE as of 1 August 2026. Chemo Pharma Laboratories Ltd (CHEMOPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹12.53 (Cr). The 52-week high for CHEMOPH share price is ₹150.75 and the 52-week low is ₹95.00. The company has a Return on Equity (ROE) of -164.24% and a debt-to-equity ratio of 0.00.
Chemo Pharma Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Chemo Pharma Laboratories Ltd share price chart: 8.84% return over the past month. 52-week high ₹150.75, 52-week low ₹95.00.
Chemo Pharma Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹117.20 | ₹117.20 | ₹107.00 | ₹109.00 | 1.10K (Cr) | |
| ₹105.55 | ₹118.00 | ₹105.55 | ₹106.55 | 382.00 (Cr) | |
| ₹120.00 | ₹120.00 | ₹105.00 | ₹112.30 | 5.06K (Cr) | |
| ₹115.00 | ₹118.75 | ₹114.00 | ₹117.50 | 901.00 (Cr) | |
| ₹102.00 | ₹108.95 | ₹102.00 | ₹105.25 | 578.00 (Cr) | |
| ₹107.10 | ₹116.00 | ₹107.10 | ₹107.95 | 575.00 (Cr) | |
| ₹137.00 | ₹137.00 | ₹114.00 | ₹116.85 | 358.00 (Cr) | |
| ₹143.70 | ₹143.70 | ₹117.00 | ₹123.60 | 2.00K (Cr) | |
| ₹112.80 | ₹135.35 | ₹106.00 | ₹128.80 | 2.44K (Cr) | |
| ₹103.60 | ₹113.50 | ₹103.55 | ₹112.80 | 116.00 (Cr) |
Chemo Pharma Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹105.05 | ₹143.70 | ₹95.00 | ₹109.00 | +3.76% | |
| ₹131.50 | ₹138.00 | ₹95.00 | ₹107.25 | -18.44% | |
| ₹115.00 | ₹141.80 | ₹112.00 | ₹130.85 | +13.78% | |
| ₹118.75 | ₹132.95 | ₹112.00 | ₹114.35 | -3.71% | |
| ₹128.50 | ₹150.75 | ₹109.05 | ₹118.75 | -7.59% |
AI Research Briefing
Powered by Gemini · 2026-08-01
A non-operational shell company with zero revenue and negative return metrics, posing extreme capital lockup risk.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The company generated zero operational revenue in recent quarters, posting an quarterly net loss of ₹0.07 Cr for March 2026. Production facilities remain completely inactive, leaving the business dependent entirely on financial investment income. The corporate name change to Starsource Multitrade Limited in October 2025 signals a complete exit from core pharmaceutical operations.
CORE STORY (THE REAL GAME)
This is an illiquid shell company trade, not a pharmaceutical business. The pharma moniker is purely historical legacy. With zero core manufacturing and no commercial scale, trading activity is driven entirely by retail speculative flows and illiquidity traps rather than operational fundamentals.
- No major catalysts found after live search
- Zero operational revenue posted in latest filings
- 6-month price momentum down 42.68% reflecting severe liquidity drain
- Formal announcement of reverse merger or strategic acquisition
- Promoter equity injection or change in management
- Liquidation or asset sale disclosures
- Micro/SME cap with extreme illiquidity risk and potential exit trap
- Non-operational core business generating zero sales revenue
- Severe return degradation with ROE and ROCE at -164.24%
Promoters hold 27.89% (flat), FII holding is 0.0% (flat), and DII holding is a negligible 0.37% (flat). Zero institutional accumulation.
Broader Indian pharma sector benefits from government PLI schemes, but non-producing shell companies derive zero structural benefit.
Poor cash flow quality with 5-year FCF at ₹-11.19 Cr.
Operational turnaround is unlikely without a complete change of business model. High risk of continued capital erosion.
Primary Thesis Risk
Complete capital loss due to lack of operations and extreme micro-cap illiquidity.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Chemo Pharma Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Chemo Pharma Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CHEMOPH across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (79.41%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (-164.24%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-164.24%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Negative Free Cash Flow (₹-11.19 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (27.89%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Limited Institutional Interest (FII+DII: 0.37%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Chemo Pharma Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Chemo Pharma Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Chemo Pharma Laboratories LtdChemo Pharma La...Selected✓ CHEMOPH • 506365 | 8/100 | ₹109.00₹109 | ₹12.53₹12.53 | — — | -164.24%Poor -164.24% Poor | -164.24%Poor -164.24% Poor | 0.00Excellent 0.0 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Chemo Pharma Laboratories Ltd Quarterly Performance
Latest quarterly metrics for CHEMOPH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
79.41%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Chemo Pharma Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CHEMOPH — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Chemo Pharma Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Chemo Pharma Laboratories Ltd (CHEMOPH) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Chemo Pharma Laboratories Ltd
About CHEMOPH (Chemo Pharma Laboratories Ltd)
Chemo Pharma Laboratories Ltd is a historical pharmaceutical entity rooted in the Indian subcontinent, specifically Mumbai. Established in 1942, the company boasts a rich legacy in... the research, development, and manufacture of pharmaceutical and bulk drug products. For decades, Chemo Pharma Laboratories Ltd played a significant role in the healthcare sector, contributing to the production of vital medications and active pharmaceutical ingredients. Their legacy is intertwined with the evolution of the pharmaceutical industry in India, having navigated changing regulatory landscapes and technological advancements during their active years. The company's historical operations involved a range of activities, from research and development to large-scale production and distribution, supporting healthcare needs across a broad spectrum. The company's journey took an interesting turn in October 2025, marking a significant shift in its identity and strategic direction. At this time, Chemo Pharma Laboratories Ltd underwent a transformation, changing its name to Starsource Multitrade Limited. This change signaled a departure from its established focus on pharmaceuticals and a move towards new ventures and opportunities. While the precise details of this transition remain subject to public information, the renaming marked a pivotal moment in the company's history, indicating a strategic realignment of its business model and objectives. The former identity as Chemo Pharma Laboratories Ltd remains a testament to its pharmaceutical past, forever etched in the annals of the Indian pharmaceutical industry. As Starsource Multitrade Limited, the company experienced a period where its operational activities became limited. While the company had a legacy in the pharmaceutical sector, Starsource Multitrade Limited did not have significant operations and was transitioning away from the active production of pharmaceutical and bulk drug products. The change was a reflection of the evolving business climate, and the company's efforts to change and adapt to new opportunities. The journey from Chemo Pharma Laboratories Ltd to Starsource Multitrade Limited encapsulates the dynamic nature of the business world, where companies must constantly reassess their strategies and navigate shifting market forces to remain relevant and competitive.
Company Details
Key Leadership
CHEMOPH Share Price: Frequently Asked Questions
What is the current share price of Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd (CHEMOPH) trades at ₹109.00 on NSE and BSE. Market cap ₹12.53 (Cr). Educational data only.
What is the P/E ratio of Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd has a Bull Run score of 8/100 based on 25+ financial parameters.
Does Chemo Pharma Laboratories Ltd pay dividends?
Chemo Pharma Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd has ROE of -164.24%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd has debt-to-equity of 0.00.
Is Chemo Pharma Laboratories Ltd a good investment?
Bull Run gives Chemo Pharma Laboratories Ltd a score of 8/100. This is not investment advice — consult a SEBI-registered advisor.